Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 3, 2012, Pages 285-289

  Lerner, Seth P ^a   Liu, Hao ^a   Wu, Meng Fen ^a   Thomas, Yngvil K ^b   Witjes, J Alfred ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Photocure   (Norway)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Fluorescence cystoscopy; Hexvix; Urinary bladder

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; BCG VACCINE;

ADULT; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CARCINOMA IN SITU; CYSTOSCOPY; DIAGNOSTIC ACCURACY; FEMALE; FLUORESCENCE CYSTOSCOPY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; URINE CYTOLOGY; WHITE LIGHT CYSTOSCOPY;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA IN SITU; CLINICAL TRIALS, PHASE III AS TOPIC; CYSTOSCOPY; FEMALE; FLUORESCENCE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; URINARY BLADDER NEOPLASMS;

EID: 84860296750     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.09.009     Document Type: Article

References (10)

1. Epstein J.I., Amin M.B., Reuter V.R., et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998, 22:1435-1448.
2. Fradet Y., Grossman H.B., Gomella L., et al. D. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: A phase III, multicenter study. J Urol 2007, 178:68-73. Discussion 73.
3. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study. J Urol 2005, 174:862-866. Discussion 866.
4. Schmidbauer J., Witjes F., Schmeller N., et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004, 171:135-138.
5. Grossman H.B., Gomella L., Fradet Y., et al. C. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007, 178:62-67.
6. McCullagh P., Nelder J. Generalized linear models. Monographs on statistics and applied probability, Vol. XXXVII 1989, Chapman and Hall, London.
7. van der Meijden A., Oosterlinck W., Brausi M., et al. Significance of bladder biopsies in Ta, T1 bladder tumors: A report from the EORTC Genito-Urinary Tract Cancer Cooperative Group EORTC-GU Group Superficial Bladder Committee. Eur Urol 1999, 35:267-271.
8. Kiemeney L.A., Witjes J.A., Heijbroek R.P., et al. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer?. A decision analysis. Members of the Dutch South-East Co-Operative Urological Group. Br J Urol 1994, 73:164-171.
9. Goh A.C., Lerner S.P. Application of new technology in bladder cancer diagnosis and treatment. World J Urol 2009, 27:301-307.
10. Mynderse L., Stenzl A., Denzinger S., et al. Hexaminolevulinate fluorescence cystoscopy improves detection and resection of papillary bladder cancer lesions and reduces early recurrences. J Urol 2009, 181. [Abstract 1909].